Metabolic dysfunction-associated steatotic liver disease
ICD-10 K76.0 · ICD-11 DB92

Treatment of Nonalcoholic Fatty Liver Disease (MASLD) with Dyslipidemia

When metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly classified as nonalcoholic fatty liver disease (NAFLD) — occurs alongside dyslipidemia, management must address both the liver disease and the elevated atherosclerotic cardiovascular risk that this combination entails.

Clinical scenario: Nonalcoholic fatty liver disease with co-occurring dyslipidemia — requiring lipid risk stratification integrated into the overall treatment plan.

Treatment approach (partial)

First-line therapy in this setting involves a lipid-lowering drug class selected according to individual lipid risk levels and atherosclerotic CVD risk scores. Intensity selection, clinical decision criteria, and the full structured approach are detailed in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

  • Management of dyslipidemia in NAFLD should include the use of moderate-intensity to high-intensity statins as first-line therapy based on lipid risk levels and atherosclerotic CVD risk scores.
  • Statins are safe and recommended for CVD risk reduction in patients with NAFLD across the disease spectrum, including compensated cirrhosis.

DOI: 10.1097/HEP.0000000000000323

View source ↗